Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like bloodbath tomorrow, unfortunately!
2 sleeps, I like that:)
Great, I'm with you on the speed bump and the mirrors, I'm in longterm also! Do you live here in the states? What time should we be looking for a annoucement from the company? I'm in tennessee which is central time, I thought I saw where on the ASX, there were certain times they could release news, is that correct? Hopefully news tomorrow night our time!
Thanks for sharing your thoughts! It's a short and basher party over on yahoo with scam being the favorite word of the day...What time do you think we would see a announcement from the company before they go back to trading, I'm guessing sometime at night here in the states? TIA
Suspended trading for ongoing talks: should start trading sometime next week. Also, picked this up from yahoo someone called CFO found out this is a straight capital raise only do the high demand for their new breast cancer product, ramping up production. Take it with a gran of salt coming from a mssg board but he sounds legit imo!
http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=GTG&timeframe=D&period=W
Suspended trading for ongoing talks:
http://www.asx.com.au/asx/statistics/announcements.do?by=asxCode&asxCode=GTG&timeframe=D&period=W
Not the first time this GENE has been halted, check it out:
http://www.patentlicensing.com.au/patent-licensing-articles/2004/9/22/preagreement-halt-at-genetic-technologies/
What do you think is going on where they would halt the company on both exchanges? Any ideas? thx
I have no idea, I never seen a company halt a stock to raise capital selling shares???
Trading halted by the company on the ASX exhange:
http://www.asx.com.au/asxpdf/20110712/pdf/41zqnstc9ggsrg.pdf
Their website is the best place.
http://www.gtglabs.com.au/corporate
Bought some today, differently needed a pull back, hope the trend is up!
Hey surf, looking to start a position in GENE any ideas chart wise on where this may be going, thanks!
Thanks Surf, was looking to get in but it has gotton away from me at this point, will hopefully wait for it to come back alittle, damn this stock flies!
Looking to take a position, can anyone tell me if insiders or funds own any shares. Yahoo shows the O/S at 13.49 mil and the float at 5.72 mil, who owns all the share? Thanks in advance
Shares Outstanding5: 13.49M
Float: 5.72M
% Held by Insiders1: N/A
% Held by Institutions1: N/A
Pulled this from yahoo, no link provided but it looks like Richards won't be writing the article. fwiw
Jeremy Richards: (RNN) I have decided NOT to write another article. I believe this company offers far greater Upside reward than risk. Watch for Phase2 news
Jeremy Richards: (AEZS) bought today.(SIRI) bought today.(BIDU) bought today. (RNN) I will have a new article out soon on why RNN is a takeover target.about 2 hours ago | | Email Jeremy Richards: Rexahn Pharmaceuticals,(RNN) I believe this is a takeover play. Buying now should be a win win for investors. $3 Analyst Target. Buyout $5+
http://seekingalpha.com/symbol/rnn/stocktalks
From Simon Monger's 6/16 Column
Rexahn Pharmaceuticals Inc. (RNN, Free Analysis), a clinical stage biopharmaceutical company focused on cancer and CNS diseases, was initiated with a Buy rating and $3.00 per share price target by Brean Murray ahead of the opening bell. At a significant 144% premium to the current market price, the analyst’s price target reflects a very bullish stance on the company’s future outlook.
While the stock has been beaten down in recent months by Dr. Chang Ahn’s decision to step down from CEO and a recent dilutive capital raise, the biopharmaceutical company has made considerable progress in advancing its clinical trials and Ahn has been increasing his stake in the company. As a result, this is one stock that is potentially misunderstood by the market and could be a bargain at these levels.
End of 2nd quarter coming, fund mgr moving money around. Bids look very good here!
Moving up nicel today, still getting large bid support. Lets see if it can hold into the weekend!
Rexahn Pharma Initiated with a Buy Rating
Rexahn Pharmaceuticals Inc. (RNN, Free Analysis), a clinical stage biopharmaceutical company focused on cancer and CNS diseases, was initiated with a Buy rating and $3.00 per share price target by Brean Murray ahead of the opening bell. At a significant 144% premium to the current market price, the analyst’s price target reflects a very bullish stance on the company’s future outlook.
While the stock has been beaten down in recent months by Dr. Chang Ahn’s decision to step down from CEO and a recent dilutive capital raise, the biopharmaceutical company has made considerable progress in advancing its clinical trials and Ahn has been increasing his stake in the company. As a result, this is one stock that is potentially misunderstood by the market and could be a bargain at these levels.
Huge blocks showing on the bid, 250k, 550k and 747k....poss funds trying to load at this level?!?
BETHESDA, Md., June 5, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB:NWBO.ob - News) today announced that it has put in place a series of financing arrangements, including a $3 million investment already received, and access to up to $25 million of further funding on fixed, specified and favorable terms, at such times and in such amounts as the Company chooses. This series of financing arrangements will provide a strong financial foundation for completion of the Company's ongoing 240-patient clinical trial of DCVax®-L for the treatment of Glioblastoma multiforme (GBM) brain cancer, and will also provide for certain other programs in the Company's near term pipeline.
(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)
As the first component of the overall financing arrangements, the initial $3 million investment has been provided by a multi-billion dollar institutional investment fund based in Minnesota. The investment is structured as a convertible note with warrants. The note is not convertible until maturity, 18 months after closing, and is only convertible into unregistered restricted stock at that time. The conversion price of the note is a fixed, specified price per share, at a three percent (3%) discount from the market price at the time of the note agreement (the volume weighted average price over the 10 trading days ending on the May 31st closing date), and the warrant coverage is one hundred percent without any cashless exercise provision.
As such, this $3 million investment reflects a long-term interest in the Company on the part of the investor, and will provide for the continued acceleration of the Company's GBM brain cancer clinical trial while the arrangements for the $25 million follow-on facility are being implemented.
"We are pleased to receive strong support and long-term interest from a major institutional investor," commented Dr. Alton Boynton. "It reflects a growing recognition in the investor community of NWBT's progress operationally, and NWBT's significant growth potential."
As the second component of the overall financing arrangements, Toucan Partners has agreed to provide an equity facility to enable NWBT to issue registered, tradable shares for future financings of up to $25 million over a 30-month period. The shares involved in this equity facility will be registered in several tranches, and the 30-month period will begin on the effective date of the first registration statement.
Any use of this equity facility will be entirely in the Company's discretion. If the Company elects to make maximum use of the facility, it can potentially cover all of the remaining costs for the ongoing 240-patient GBM brain cancer clinical trial to complete the patient enrollment and reach the primary endpoint of the trial, as well as other near term initiatives.
Upon notification by the Company, Toucan will be obligated to purchase a specified amount of stock based upon a backward-looking, fixed price formula of ninety-five percent (95%) of the average of the three (3) lowest closing bid prices of the Company's common stock during the fifteen (15) trading days prior to the Company's notification date. Toucan will receive a one percent (1%) commitment fee for the facility upon execution, and a five percent (5%) fee on the sales of shares under the facility when the sales are executed.
"This equity facility marks an important step in taking control of our own financing destiny, as it will enable us to access a much wider pool of investors who have been expressing interest but can only invest in tradable shares, while also providing the comfort of knowing that the equity facility will be administered by a major shareholder whose interests are aligned with the Company's," commented Dr. Alton Boynton. "The facility also affords us substantially more favorable terms than have been available to us in financings with unregistered shares or convertible debt."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.
For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.
Two weeks ago Northwest Biotherapeutics announced a partnering agreement with Fraunhofer, the largest applied research foundation in Europe. Shares have since near-doubled in value.
Northwest's vaccine, DCvax-Brain, also addresses the largely unmet need for better brain cancer treatment. Its latest partnership agreement was especially significant in the approval to administer DCvax-Brain to patients under compassionate care uses in Europe. This may mean the inflow of incremental revenues and cash as a means of financing ongoing operations.
DCVax-Brain, like ImmunoCellular's ICT-107, has seen phenomenal clinical data in previous trials, as noted here. Also, 69% of patients have survived beyond two years, significantly greater than the standard-of-care rate of 26%. Moreover, Northwest Biotherapeutics prepared the following schedule to gauge DCVax's effectiveness relative to Dendreon's Provenge, and the current standard-of-care, which includes surgery, radiation therapy and Temodar, a compound distributed by Merck (MRK).
Click to enlarge
Like Northwest Biotherapeutics, ImmunoCellular Therapeutics has also considered the possibility of licensing out its technology and/or the possibility of a takeover by a large pharmaceutical company in later stages. When asked about competitive advantage at his firm, IMUC CEO Manish Singh responsed:
We don’t measure ourselves to matrices such as how many people we have working under us, or how many trials we can run; rather, focus belongs to running clinical trials where we believe we can demonstrate significant value inherit in our products. For example, instead of undergoing a single arm phase II trial, we proceeded to implement a randomized, double blinded trial as means for proving efficacy. This would particularly cater to a large pharmaceutical company from an acquisition perspective.
Earlier this year Amgen took over privately-held Biovex, a biotechnology firm that was developing a vaccine for head and neck cancer, for $1B. Biovex's cancer drug showed efficacy that fell short of Northwest Biotherapeutics’ DCvax, at least as observed in earlier trials. Yet the resemblance shows the potential inherit in new generation immunotherapy-based firms. This is the future of cancer therapy.Remember, Dendreon wasn't built in a day.
Disclosure: I am long AMGN, NWBO.OB, IMUC.OB.
Additional disclosure: The opinion expressed herein does not constitute a buy or sell recommendation for any securities. Please be advised that you should consult your independent investment advisor before making any investment decisions. View our full disclaimer at timelesswealth.net.
http://seekingalpha.com/article/272805-i...
Could be switched from prescription to OTC, that's huge imo!! You can play this stock for early 2012 or hold for all 3 products to come out and see where they take this stock. If all goes right with the trials here and abroad, the potential is mindboggling!
The U.S. composition-of-matter patent on the iferanserin ointment expires in 2015, but existing legislation would add another five years of market exclusivity. “If that’s the case, we have an ideal product that could be switched from a prescription base to an over-the-counter product,” he says. On the other hand, Ventrus has filed new concentration-range patents which, if issued, would grant the hemorrhoid product 20 years of market exclusivity.
Dr. Ellison says Ventrus has milestones planned in each of the next six quarters, which either “reduces risk or exemplifies progress.”
http://biotuesdays.com/2011/01/25/ventru...
Two report on the company
http://www.proactivenewsroom.com/Default...
http://www.proactivenewsroom.com/Default...
Ventrus Biosciences (NASDAQ:VTUS) is moving forward in clinical research towards this day which for the greater majority of companies recently has resulted in a sharp incline in share price. The Company is seated firmly as a leader in gastrointestinal products in areas of unmet need, specifically hemorrhoids, anal fissures, and fecal incontinence. While many other companies are focused on highly-competitive areas, Ventrus has specialized its direction and is prepared to capitalize on the 12.5 million Americans that suffer from hemorrhoids; 7 million affected by fecal incontinence; and more than 4 million that must cope with anal fissures. There are currently no FDA-approved therapies for these debilitating conditions, yet an exorbitant amount of money spent yearly by the population in attempts to remedy the situations.
As an unapproved solution, over 4 million prescriptions are written annually in the States for therapies to treat hemorrhoids alone with more than 22 million over the counter units sold. Ventrus estimates to sell their hemorrhoid therapy for $350 per unit. Without ever making the grand assumptions that 100 percent of market share would be captured, the scenario represents a value of $7.7 billion based on current figures. That goes without mentioning the potential revenue that can be derived from fecal incontinence and anal fissure patients which could push the total considerably higher.
With a total debt of less than $3 million, three drugs in late-stage clinical development and only 9.3 million fully-diluted shares, Ventrus is already starting to capture the attention of the investment community. While it may be true for a biotechnology company that “He conquers who endures,” in the world of biotech investing the phrase “the early bird catches the worm” may be more appropriate.
The Best-Performing Biotech Stocks So Far This Year
May. 12 2011 - 12:55 pm | 679 views | 0 recommendations | 0 comments
By MATTHEW HERPER
Because, I was wondering, and I thought you might be curious, too. Here is a screen, via FactSet, of the best-performing biotech and drug stocks over the year so far. I’ve taken some, but not many, efforts to screen out penny stocks.
Company
Ticker
Total Return, Year-To-Date
Price, 5/09/11
Genetic Technologies Ltd. ADS
GENE
668.7
8.11
Accelr8 Technology Corp.
AXK
284.8
3.81
Ventrus Biosciences Inc.
VTUS
205.9
20.25
Dynatronics Corp.
DYNT
177.8
1.75
Novogen Ltd. ADS
NVGN
174.5
1.40
Biolase Technology Inc.
BLTI
172.4
4.72
Pharmasset Inc.
VRUS
146.1
107.20
DUSA Pharmaceuticals Inc.
DUSA
136.7
5.80
TranS1 Inc.
TSON
120.7
4.59
NeoProbe Corp.
NEOP
118.4
4.50
S&P 500
SP50
7.0
1,346.29
Several of these really catch my attention. Ventrus, one of the most successful IPOs of the year, is developing a treatment for hemorrhoids. Pharmasset, maker of experimental Hep C drugs, has just been on fire, stock-wise. BioLase has been around a long time — I profiled them years ago. I don’t know why the stock is up so much. DUSA is a dermatology company.
Why are these stocks up? Which ones are buys and which ones have run up too far? What does this list have to tell us about the state of the drug business? I’d be curious what readers have to say.
Two report on the company, with the latest upgrade report:
http://www.proactivenewsroom.com/Default.aspx?app=LeadgenDownload&shortpath=docs%2fRodman_%26_Renshaw_VTUS_2011-05-03.pdf
http://www.proactivenewsroom.com/Default.aspx?app=LeadgenDownload&shortpath=docs%2fVTUS.National.2.1.2011.pdf
Ventrus Biosciences (NASDAQ:VTUS) is moving forward in clinical research towards this day which for the greater majority of companies recently has resulted in a sharp incline in share price. The Company is seated firmly as a leader in gastrointestinal products in areas of unmet need, specifically hemorrhoids, anal fissures, and fecal incontinence. While many other companies are focused on highly-competitive areas, Ventrus has specialized its direction and is prepared to capitalize on the 12.5 million Americans that suffer from hemorrhoids; 7 million affected by fecal incontinence; and more than 4 million that must cope with anal fissures. There are currently no FDA-approved therapies for these debilitating conditions, yet an exorbitant amount of money spent yearly by the population in attempts to remedy the situations.
As an unapproved solution, over 4 million prescriptions are written annually in the States for therapies to treat hemorrhoids alone with more than 22 million over the counter units sold. Ventrus estimates to sell their hemorrhoid therapy for $350 per unit. Without ever making the grand assumptions that 100 percent of market share would be captured, the scenario represents a value of $7.7 billion based on current figures. That goes without mentioning the potential revenue that can be derived from fecal incontinence and anal fissure patients which could push the total considerably higher.
With a total debt of less than $3 million, three drugs in late-stage clinical development and only 9.3 million fully-diluted shares, Ventrus is already starting to capture the attention of the investment community. While it may be true for a biotechnology company that “He conquers who endures,” in the world of biotech investing the phrase “the early bird catches the worm” may be more appropriate.